All Stories

  1. First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA
  2. Incorporating Metastatic Disease Burden into Prognostic Assessment in Metastatic Castration-Resistant Prostate Cancer: The MIRA Score
  3. Wearable Devices and Machine Learning in Cardiovascular Monitoring: Current Evidence and Future Directions for Precision Medicine
  4. First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA
  5. First-line maintenance therapy patterns in BRCA wild-type and HRD-negative advanced epithelial ovarian cancer: A European real-world study.
  6. Molecular fingerprints of drug-resistant epilepsy identified through liquid biopsy profiling
  7. On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials
  8. Eprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparib
  9. The Current Landscape of Artificial Intelligence in Positron Emission Tomography (PET) Imaging Across the Cancer Continuum
  10. Genetically Optimized Modular Neural Networks for Precision Lung Cancer Diagnosis: Exploratory Study of Novel Approach
  11. Coronavirus disease 2019-associated mucormycosis and cytomegalovirus infection: a case report
  12. A multi-modal approach for decision making in bladder cancer
  13. Unlocking precision: Bispecific T cell engagers and the next frontier in uro-oncology
  14. Idiopathic Inflammatory Myopathy With Normal Creatine Kinase Levels in an Elderly Patient: A Diagnostic Challenge
  15. Redefining Chemotherapy-Related Headaches: From Pathobiology to Differential Diagnosis and Management
  16. From Crisis to Cancer: Diabetic Ketoacidosis Unmasking a Malignancy of Unknown Origin
  17. Cancer Reversion Therapy: Prospects, Progress and Future Directions
  18. Efficacy of ketogenic metabolic therapy as an adjuvant to the current standard of care in the treatment of glioblastoma: A systematic review of clinical trials
  19. Molecular engines driving biogenesis, trafficking and release of exosomes: SNARE proteins
  20. The risk of lung cancer from vaping or e-cigarette usage: a systematic review
  21. Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review
  22. Resolution of Persistent Fever and Systemic Inflammation in a Metastatic Gastrointestinal Stromal Tumour (GIST) With Imatinib
  23. Advancing circular economy practices in radiography: a narrative review of sustainable medical imaging
  24. Therapeutic opportunities in EBV-positive gastric cancer subtypes
  25. SKP2 at the crossroads of proliferation and immune evasion: a new target in the tumor microenvironment
  26. Smart Nanomedicines for Neurodegenerative Diseases: Empowering New Therapies with Molecular Imaging and Artificial Intelligence
  27. Enhancing home rehabilitation through AI-driven virtual assistants: a narrative review
  28. Generative artificial intelligence in predictive analysis of diabetes and its complications: a narrative review
  29. Smart emergency care: a narrative review of predictive machine learning models
  30. Comparative Analysis of Large Language Models in Dermatological Diagnosis: An Evaluation of Diagnostic Accuracy
  31. The evolution of targeted intra operative radiotherapy in early breast cancer
  32. The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation
  33. Agnostic Biomarkers and Molecular Signatures in Colorectal Cancer—Guiding Chemotherapy and Predicting Response
  34. Immune Organoids: A Review of Their Applications in Cancer and Autoimmune Disease Immunotherapy
  35. Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
  36. Enhancing Parkinson’s disease prediction using meta-heuristic optimized machine learning models
  37. Evaluating AI adoption in healthcare: Insights from the information governance professionals in the United Kingdom
  38. The Impact of AI-Driven Chatbot Assistance on Protocol Development and Clinical Research Engagement: An Implementation Report
  39. Stacked Ensemble Learning for Classification of Parkinson’s Disease Using Telemonitoring Vocal Features
  40. Urban Microclimates and Their Relationship with Social Isolation: A Review
  41. Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis
  42. Pathobiology and Molecular Pathways Implicated in Osteosarcoma Lung Metastasis: A Scoping Review
  43. Reversing Epigenetic Dysregulation in Neurodegenerative Diseases: Mechanistic and Therapeutic Considerations
  44. Disentangling the Gordian Knot of parasympathetic innervations in arthritic joint
  45. AI-Driven Advancements in Orthodontics for Precision and Patient Outcomes
  46. The current landscape of artificial intelligence in computational histopathology for cancer diagnosis
  47. Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
  48. Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment
  49. AI-Driven Advances in Low-Dose Imaging and Enhancement—A Review
  50. Spinal MRI in Patients with Suspected Metastatic Spinal Cord Compression: A Quality Improvement Audit in a District General Hospital in Kent, UK
  51. Diagnosis and Treatment of Gestational Non-Epithelial Ovarian Cancer: A Systematic Review
  52. Male Breast Cancer: A Single Institutional Clinicopathological Profiling
  53. Enhancing Ophthalmic Diagnosis and Treatment with Artificial Intelligence
  54. Precision oncology through next generation sequencing in hepatocellular carcinoma
  55. Spotlight on Lung Cancer Disparities in India
  56. Molecular biomarkers of glial activation and injury in epilepsy
  57. Integrating AI into Cancer Immunotherapy—A Narrative Review of Current Applications and Future Directions
  58. Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
  59. Molecular Biology of Cancer—Interplay of Malignant Cells with Emerging Therapies
  60. Construction of a prognostic survival model with tumor immune-related genes for breast cancer
  61. An overview of immune checkpoint inhibitor toxicities in bladder cancer
  62. An orthogonal approach for analysis of underivatized steroid hormones using ultrahigh performance supercritical fluid chromatography-mass spectrometry (UHPSFC-MS)
  63. AI-Guided Cancer Therapy for Patients with Coexisting Migraines
  64. Artificial Intelligence – Guided Cancer Therapy for Patients with Migraine Comorbidities
  65. Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer
  66. Paediatric Anatomical Models in Radiotherapy Applications
  67. Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape
  68. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
  69. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
  70. lncRNA Biomarkers of Glioblastoma Multiforme
  71. Large Language Models in Oncology: Revolution or Cause for Concern?
  72. The Application of Radiomics and AI to Molecular Imaging for Prostate Cancer
  73. A novel PD-1/PD-L1 pathway-related seven-gene signature for the development and validation of the prognosis prediction model for breast cancer
  74. A rare case of metaplastic breast carcinoma from India: Towards precision oncology
  75. Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma – A Meta-analysis
  76. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4
  77. Exosomes in Renal Cell Cancer: Diagnostic and Therapeutic Nanovehicles
  78. Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum
  79. Medical oncology: challenges in 2022
  80. Frontiers of Molecular Biology of Cancer
  81. Immune checkpoint inhibitors in patients with cancers of unknown primary
  82. Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness
  83. Frontiers of Ovarian Carcinosarcoma
  84. COVID-19 Associated Mucormycosis and Cytomegalovirus Infection – A Case Report
  85. Renal Cell Cancer – Insights in Drug Resistance Mechanisms
  86. The integration of palliative care with oncology: the path ahead
  87. Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine
  88. Exosomes in the Diagnosis and Treatment of Renal Cell Cancer
  89. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study
  90. Gestational Renal Cell Cancer – An Update
  91. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
  92. Re: Pain and Health-related Quality of Life with Olaparib Versus Physician’s Choice of Next-generation Hormonal Drug in Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An O...
  93. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer – a Retrospective UK Single-Center Study
  94. Emerging Hallmarks of the Tumour Microenvironment of Gliomas and the Interplay with Immunotherapy
  95. Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors
  96. Advances in adoptive T-cell therapy for metastatic melanoma
  97. Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours
  98. Impact of COVID-19 on cancer services and patients’ outcomes: a retrospective single-center study
  99. State-of-the-Art Molecular Oncology in UK
  100. Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy
  101. Clinico-Pathological Factors Determining Recurrence of Phyllodes Tumors of the Breast: The 25-Year Experience at a Tertiary Cancer Centre
  102. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
  103. Prostate cancer—what about oligometastatic disease and stereotactic ablative radiotherapy?—a narrative review
  104. From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary
  105. Constrictive Pericarditis–A Cloak Camouflaging Lymphoma
  106. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
  107. Aberrations of DNA Repair Pathways in Prostate Cancer—The State of the Art
  108. HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK
  109. Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
  110. Efficacy and Safety of COVID-19 Vaccines—An Update
  111. A Primary Mediastinal Monophasic Spindle-Cell Synovial Sarcoma with Superior Venacaval Obstruction
  112. Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy
  113. Surgery for T4 Colorectal Cancer in Older Patients: Determinants of Outcomes
  114. Chromosomal instability in cancers of unknown primary
  115. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
  116. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
  117. COVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
  118. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
  119. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls
  120. Sarcoma of unknown primary: myth or reality?
  121. Systematic review of the CUP trials characteristics and perspectives for next-generation studies
  122. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
  123. Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer
  124. Epilepsy and Diagnostic Dilemmas: The Role of Language and Speech-Related Seizures
  125. Metastatic Anorectal Melanoma Presenting as Seizures: An Infrequent Culprit
  126. Case of cerebral venous thrombosis on a patient with background of nephrotic syndrome
  127. Systematic review of fetal and placental metastases among pregnant patients with cancer
  128. Non-Epithelial Ovarian Cancers: How Much Do We Really Know?
  129. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
  130. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry
  131. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
  132. The Experience of a Single NHS England Trust on the Impact of the COVID-19 Pandemic on Junior and Middle-Grade Doctors: What Is Next?
  133. Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
  134. Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
  135. Unraveling the Wide Spectrum of Melanoma Biomarkers
  136. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary
  137. Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology
  138. Cancer-Associated Thrombosis: A New Light on an Old Story
  139. Comparative genomic characterization of melanoma of known and unknown primary
  140. Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities
  141. Management of Metastatic Spinal Cord Compression in Secondary Care: A Practice Reflection from Medway Maritime Hospital, Kent, UK
  142. Melanoma of unknown primary: New perspectives for an old story
  143. Current and future immunotherapy approaches in ovarian cancer
  144. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
  145. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review
  146. Metformin and ovarian cancer: the evidence
  147. NOTCH signalling in ovarian cancer angiogenesis
  148. Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered
  149. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
  150. Ovarian cancer: state of the art and perspectives of clinical research
  151. Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches
  152. Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence
  153. An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
  154. Wise Management of Ovarian Cancer: On the Cutting Edge
  155. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
  156. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
  157. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
  158. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
  159. PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
  160. The Developing Story of Predictive Biomarkers in Colorectal Cancer
  161. Ovarian carcinosarcoma: Current developments and future perspectives
  162. Management of Recurrent Uterine Cervical Cancer
  163. Spinal Ewing Sarcoma Debuting with Cord Compression: Have We Discovered the Thread of Ariadne?
  164. Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges
  165. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives
  166. Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature
  167. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives
  168. Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects
  169. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
  170. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer
  171. Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
  172. Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review
  173. Current and future biomarkers in colorectal cancer
  174. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
  175. Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies
  176. Cancer specific risk in multiple sclerosis patients
  177. Pancreatic resection for renal cell carcinoma metastasis: An exceptionally rare coexistence
  178. Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor
  179. Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis
  180. Lung cancer in pregnancy: Report of nine cases from an international collaborative study
  181. Renal cell carcinoma in pregnancy: a rare coexistence